These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38899179)
1. Risk Factors for Severe Hypertension and Proteinuria After Treatment With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Among Patients With Cancer. Hanna PE; Anumolu RK; Motwani SS; Chen KL; Katz-Agranov N; Green-Lingren O; Yilmam OA; Jhaveri KD; Kitchlu A; Kala J; Sise ME; Gupta S Kidney Int Rep; 2024 Jun; 9(6):1897-1902. PubMed ID: 38899179 [No Abstract] [Full Text] [Related]
2. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Robinson ES; Matulonis UA; Ivy P; Berlin ST; Tyburski K; Penson RT; Humphreys BD Clin J Am Soc Nephrol; 2010 Mar; 5(3):477-83. PubMed ID: 20056761 [TBL] [Abstract][Full Text] [Related]
3. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. Faruque LI; Lin M; Battistella M; Wiebe N; Reiman T; Hemmelgarn B; Thomas C; Tonelli M PLoS One; 2014; 9(7):e101145. PubMed ID: 24988441 [TBL] [Abstract][Full Text] [Related]
4. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer. Kato T; Mizuno R; Miyake H Int J Urol; 2024 May; 31(5):465-474. PubMed ID: 38318663 [TBL] [Abstract][Full Text] [Related]
5. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Zhu X; Wu S; Dahut WL; Parikh CR Am J Kidney Dis; 2007 Feb; 49(2):186-93. PubMed ID: 17261421 [TBL] [Abstract][Full Text] [Related]
6. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management. Tesařová P; Tesař V Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab. Hanna RM; Abdelnour L; Hasnain H; Selamet U; Kurtz I SAGE Open Med Case Rep; 2020; 8():2050313X20907033. PubMed ID: 32110410 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987 [TBL] [Abstract][Full Text] [Related]
10. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Maynard SE; Min JY; Merchan J; Lim KH; Li J; Mondal S; Libermann TA; Morgan JP; Sellke FW; Stillman IE; Epstein FH; Sukhatme VP; Karumanchi SA J Clin Invest; 2003 Mar; 111(5):649-58. PubMed ID: 12618519 [TBL] [Abstract][Full Text] [Related]
11. Elevated soluble VEGF receptor sFlt-1 correlates with endothelial injury in IgA nephropathy. Zhai YL; Zhu L; Shi SF; Liu LJ; Lv JC; Zhang H PLoS One; 2014; 9(7):e101779. PubMed ID: 25007257 [TBL] [Abstract][Full Text] [Related]
12. [Angiogenesis inhibitors: mechanism of action and nephrotoxicity]. Clou E; Luque Y Nephrol Ther; 2022 Feb; 18(1):1-6. PubMed ID: 34838486 [TBL] [Abstract][Full Text] [Related]
13. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Hanna RM; Lopez EA; Hasnain H; Selamet U; Wilson J; Youssef PN; Akladeous N; Bunnapradist S; Gorin MB Clin Kidney J; 2019 Feb; 12(1):92-100. PubMed ID: 30746134 [TBL] [Abstract][Full Text] [Related]
14. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Launay-Vacher V; Deray G Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005 [TBL] [Abstract][Full Text] [Related]